切换至 "中华医学电子期刊资源库"
高级检索
中华妇幼临床医学杂志(电子版)

中华妇幼临床医学杂志(电子版) ›› 2017, Vol. 13 ›› Issue (03) : 332 -336. doi: 10.3877/cma.j.issn.1673-5250.2017.03.016

所属专题： 文献；

论著

CO2激光治疗有症状宫颈糜烂合并高危型人乳头瘤病毒感染
李媛媛1, 李雪丽2, 张晓梅2,†()   
  1. 1. 225002　江苏，扬州市妇幼保健院宫颈科
    2. 225001　江苏，扬州大学临床医学院　苏北人民医院生殖医学中心
  • 收稿日期:2017-02-10 修回日期:2017-05-05 出版日期:2017-06-01
  • 通信作者: 张晓梅

CO2 laser treatment for cervical erosion patients with high risk human papilloma virus infection and clinical symptoms

Yuanyuan Li1, Xueli Li2, Xiaomei Zhang2,†()   

  1. 1. Department of Cervix, Yangzhou Maternal and Child Care Service Centre, Yangzhou 225002, Jiangsu Province, China
    2. Clinical Medical School, Yangzhou University/Reproductive Medicine Center, Northern Jiangsu People′s Hospital, Yangzhou 225001, Jiangsu Province, China
  • Received:2017-02-10 Revised:2017-05-05 Published:2017-06-01
  • Corresponding author: Xiaomei Zhang
  • About author:
    Corresponding author: Zhang Xiaomei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李媛媛, 李雪丽, 张晓梅. CO2激光治疗有症状宫颈糜烂合并高危型人乳头瘤病毒感染[J]. 中华妇幼临床医学杂志(电子版), 2017, 13(03): 332-336.

Yuanyuan Li, Xueli Li, Xiaomei Zhang. CO2 laser treatment for cervical erosion patients with high risk human papilloma virus infection and clinical symptoms[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2017, 13(03): 332-336.

目的

探讨CO2激光治疗有症状宫颈糜烂合并高危型人乳头瘤病毒(HR-HPV)感染的有效性。

方法

选择2015年1至12月，在扬州市妇幼保健院采用CO2激光治疗的宫颈糜烂合并HR-HPV感染，并且伴临床症状或体征的48例宫颈糜烂患者为研究对象。统计学分析轻、中度有症状宫颈糜烂合并HR-HPV感染患者与重度有症状宫颈糜烂合并HR-HPV感染患者的治疗有效率，了解48例患者经CO2激光治疗后的人乳头瘤病毒(HPV)转阴率。

结果

CO2激光治疗后，27例轻、中度有症状宫颈糜烂合并HR-HPV感染患者的治疗有效率为96.3%(26/27)，21例重度有症状宫颈糜烂合并HR-HPV感染患者的治疗有效率为90.5%(19/21)，二者比较，差异无统计学意义(χ2＝0.050，P＝0.823)。48例患者术后3～6个月复查HPV-DNA，其中45例为HPV呈阴性，3例仍然呈阳性，术后HPV转阴率为93.8%(45/48)。

结论

CO2激光治疗是临床治疗有症状宫颈糜烂合并HR-HPV感染的有效治疗方法。

关键词: 二氧化碳, 激光疗法, 乳头状瘤病毒科, 宫颈糜烂, 女性
Objective

To investigate the effects of CO2 laser treatment for cervical erosion patients with high risk human papilloma virus(HR-HPV) infection and clinical manifestations.

Methods

From January to December 2015, 48 cervical erosion patients with HR-HPV infection combined with clinical symptoms or signs who received CO2 laser treatment in Yangzhou Maternal and Child Care Service Centre were chosen as research subjects. The difference of effective rates between cervical erosion level of mild/moderate and severe was compared. Understand the human papilloma virus (HPV) turn negative rate of the 48 patients after treatment.

Results

After CO2 laser treatment, the treatment effective rate of 27 cases of mild/moderate cervical erosion patients was 96.3% (26/27), the treatment effective rate of 21 cases of severe cervical erosion patients was 90.5%(19/21), there was no significant difference between two effective rates (χ2=0.050, P=0.823). The HPV-DNA recheck results after 3-6 months of operation of 48 patients, 45 cases turned to negative and 3 cases still remained positive. The turn negative rate of HPV was 93.8%(45/48) after operation.

Conclusions

CO2 laser treatment is an effective method for the treatment of cervical erosion patients with HR-HPV infection combine with clinical manifestations.

Key words: Carbon dioxide, Laser therapy, Papillomaviridae, Uterine cervical erosion, Female
[1]
Zou R, Xie W, Wang H, et al. Establishment and application of a method for high-risk human papillomavirus genotyping in cervical cancer tissue[J]. Clin Lab, 2016, 62(6): 1075-1085.
[2]
Tezcan S, Ozgur D, Ulger M, et al. Human papillomavirus genotype distribution and E6/E7 oncogene expression in Turkish women with cervical cytological findings[J]. Asian Pac J Cancer Prev, 2014, 15(9): 3997-4003.
[3]
Liu Y, Zhang C, Gao W, et al. Genome-wide profiling of the human papillomavirus DNA integration in cervical intraepithelial neoplasia and normal cervical epithelium by HPV capture technology[J]. Sci Rep, 2016, 6: 35427.
[4]
Wardak S. Human Papillomavirus (HPV) and cervical cancer[J]. Med Dosw Mikrobiol, 2016, 68(1): 73-84.
[5]
Li H, Wang X, Geng J, et al. Clinical study of styping detection of human papillomavirus (HPV) infection with microarray from paraffinembedded specimens of cervical cancer and precursor lesions[J]. J Nanosci Nanotechnol, 2015, 15(9): 6423-6428.
[6]
Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia[J]. Vaccine, 2008, 26(Suppl 10): K1-K16.
[7]
Benevolo M, Donà MG, Ravenda PS, et al. Anal human papillomavirus infection: prevalence, diagnosis and treatment of related lesions[J]. Expert Rev Anti Infect Ther, 2016, 14(5): 465-477.
[8]
Jiménez-Wences H, Peralta-Zaragoza O, Fernández-Tilapa G. Human papilloma virus, DNA methylation and microRNA expression in cervical cancer (review)[J]. Oncol Rep, 2014, 31(6): 2467.
[9]
Katki HA, Cheung LC, Fetterman B, et al. A joint model of persistent human papillomavirus infection and cervical cancer risk: implications for cervical cancer screening[J]. J R Stat Soc Ser A Stat Soc, 2015, 178(4): 903-923.
[10]
Einstein MH, Burk RD. Persistent human papillomavirus infection: definitions and clinical implications[J]. Papillomavirus Rep, 2001, 12(5): 119-123.
[11]
Gravitt PE, Rositch AF. HPV self-testing and cervical cancer screening coverage[J]. Lancet Oncol, 2014, 15(2): 128-129.
[12]
Castle PE, Schiffman M, Wheeler CM, et al. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(7): 1675-1681.
[13]
Asgary S, Sabbagh S, Eghbal MJ. Published endodontic articles in PubMed-Indexed journals from Iran[J]. Iran Endod J, 2012, 7(1): 1-4.
[14]
Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors[J]. Obstet Gynecol, 2013, 121(4): 829-846.
[15]
Ryu A, Nam K, Kwak J, et al. Early human papillomavirus testing predicts residual/recurrent disease after LEEP[J]. J Gynecol Oncol, 2012, 23(4): 217-225.
[16]
缪飞，王秀丽，王宏伟，等. 5-氨基酮戊酸光动力治疗宫颈高危型HPV感染[J]. 中国皮肤性病学杂志，2012, 26(1): 49-50.
[17]
陈晓静，叶菁. 阴道局部干扰素应用对宫颈高危型人乳头瘤病毒感染进程影响的临床研究[J]. 实用妇产科杂志，2016, 32(6): 450-452.
[18]
宣秀芳. 派特灵治疗宫颈HPV高危感染的临床观察[J]. 浙江实用医学，2014, 19(3): 202-203.
[19]
刘小莉. 保妇康栓治疗HPV感染疗效观察[J]. 山西中医，2015, 31(11): 53.
[20]
杨莉. 冷冻联合保妇康栓治疗慢性宫颈炎伴HPV感染的疗效分析[J]. 江苏医药，2016, 42(1): 82-83.
[21]
Schiffman M, Wentzensen N. From human papillomavirus to cervical cancer[J]. Obstet Gynecol, 2010, 116(1): 177-185.
[22]
Schiffman M, Castal PE, Jeronimo J, et al. Human papillomavirus and cervical cancer[J]. Lancet, 2007, 370(9590): 890-907.
[23]
Mayeaux EJ Jr, Cox JT. 现代阴道镜学. 魏丽惠，赵昀，译. 3版[M]. 北京：北京大学医学出版社，2016: 445-455.
[1] 陈欣, 胡莎, 罗红. 梗阻性子宫颈发育异常的超声特征及其诊断价值[J]. 中华医学超声杂志（电子版）, 2022, 19(10): 1052-1057.
[2] 汪凯林, 李舜颖, 刘强. 第5版《年轻女性乳腺癌国际共识指南》更新要点解读[J]. 中华乳腺病杂志(电子版), 2023, 17(02): 65-71.
[3] 宋景涌, 吴婷婷, 穆籣. 女性乳腺癌患者生育力保护的研究现状[J]. 中华乳腺病杂志(电子版), 2022, 16(04): 243-246.
[4] 代雯荣, 赵丽娟, 李智慧. 细胞外囊泡对胚胎着床影响的研究进展[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 616-620.
[5] 王璐, 樊杨. 子宫内膜癌相关生物标志物研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 511-516.
[6] 陈永胜, 朱健, 王军, 张永辉, 徐源佑, 丁璐璐, 陈建国, 樊健, 姚海蓉. 江苏省启东市育龄女性恶性肿瘤患者生存率变化趋势分析[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(03): 363-372.
[7] 魏权, 张燊, 陈慧佳, 邹姮, 胡丽娜. 女性生殖道微生物群与辅助生殖技术相关性研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(02): 151-155.
[8] 齐新宇, 孔菲, 赵捷, 王海燕, 乔杰. 生殖医学中的免疫学临床研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(01): 1-9.
[9] 王巍, 李顺双, 刘刚. 《2020 ACOG实践简报：孕龄≤70 d药物流产(No.225)》解读[J]. 中华妇幼临床医学杂志(电子版), 2022, 18(03): 275-281.
[10] 李晓阳, 刘柏隆, 周祥福. 大数据及人工智能对女性盆底功能障碍性疾病的诊断及风险预测[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 549-552.
[11] 李殷南, 王乾, 孙宾. 膀胱壁、逼尿肌壁厚度与老年女性膀胱过度活动症相关性研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(02): 178-182.
[12] 田利飞, 姚建锋, 张乐, 屈亚琦, 张晓龙, 权攀, 阎立昆. 子宫圆韧带去腹膜化在女性腹股沟疝患者中的应用[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(01): 56-59.
[13] 张茜, 刘叶青, 康雪莹, 孙兵兵, 刘岩, 胡丽叶, 周亚茹. 血清铁蛋白与绝经后骨质疏松症的相关性分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(03): 166-171.
[14] 夏金根, 胡诗雨. 体外二氧化碳清除技术的重症应用场景[J]. 中华重症医学电子杂志, 2023, 09(01): 40-45.
[15] 高红琴, 陈晨, 陆瑞科, 王小雨, 张敏, 李少华, 郝梨岚, 黄新程, 关凌耀, 张韵红. 外阴阴道假丝酵母菌病对女性阴道-宫颈菌群的影响研究[J]. 中华临床医师杂志(电子版), 2023, 17(06): 720-725.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号